Browse Guides  internal medicine  cardiology

Acute coronary syndrome

Prevalence
Clinical features
Differential diagnosis
Investigations
Therapy
Prevention
Prognosis
Therapy

There is no clear benefit from thrombolysis. a  

Why?

  • Patients who receive tissue plasminogen activator compared with placebo are not clearly less likely to die, have an MI or require revascularisation at 6 weeks or 1 year. a  

 

Expiry date: June 2003
Levels of Evidence used in grading these guides

Authors   CM   Ball , N   Shenker
Reviewer   I K   Jang
CAT Writers   N   Shenker , CJ   Wotton , CM   Ball , RS   Phillips